Sunday, December 22

Guwahati : The Director of Assam’s Cachar Cancer Hospital and Research Centre (CCHRC), Dr Ravi Kannan the renowned oncologist was declared as one of the awardees of Ramon Magsaysay Award 2023 for his contribution towards providing cancer care to patients in the under developed North Eastern states.  He worked earlier as a surgeon at Chennai’s Adyar Cancer Institute and was awarded Padma Shri for his contribution to the health sector.

Ravi has been announced as the distinguished recipient of the ‘Hero For Holistic Healthcare’ award on the 65th anniversary of the Ramon Magsaysay Award Foundation. The Ramon Magsaysay Award which is Asia’s premier and highest honor and is often referred to Asian equivalent of Noble Prize. The Ramon Magsaysay website recognised Ravi Kannan’s contribution and noted that “the RMAF board of trustees recognizes his devotion to his profession’s highest ideals of public service, his combination of skill, commitment, and compassion in pushing the boundaries of people-centered, pro-poor health care and cancer care, and for having built, without expectation of reward, a beacon of hope for millions in the Indian state of Assam, thus setting a shining example for all”. 

The other winners of the 65th edition of the Ramon Magsaysay Award are Eugenio Lemos (Food Sovereignty Visionary) from Timor-Leste, Miriam Coronel-Ferrer is the distinguished recipient of the Women In Peace-Building Pioneer. She is from the Philippines, and one more awardee, Korvi Rakshand of Bangladesh is a recipient of the ‘Education For All Champion’ title.  

Share.
Leave A Reply

Doctor Post is a health news portal tailored to provide updates for medical and healthcare professionals, while remaining open to others interested in accessing general health information. The content on Doctor Post is carefully created and/or edited by a dedicated team of doctors, healthcare researchers, and scientific writers.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version